OXiGENE, Inc. Announces $12 Million Public Offering
February 12, 2014 08:55 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) today announced that it has entered into definitive agreements with investors to purchase an aggregate of...
OXiGENE Announces Presentation at BIO CEO Conference on February 11th
January 30, 2014 06:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that...
OXiGENE Appoints Frederick W. Driscoll to Its Board of Directors
November 27, 2013 16:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 27, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced the...
OXiGENE Announces Preclinical Data Presentation on Novel Anticancer Compounds, Benzosuberenes, Demonstrating Potent Anti-Proliferative Activity
November 18, 2013 16:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 18, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that...
OXiGENE to Present Phase I Data Demonstrating Antitumor Activity of OXi4503 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
November 18, 2013 09:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 18, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that...
OXiGENE Reports Third Quarter 2013 Financial Results
November 12, 2013 16:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, reported financial...
OXiGENE to Present at BIO-Europe Conference on November 6th
November 04, 2013 16:30 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 4, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that...
OXiGENE Announces Third Quarter 2013 Earnings Conference Call and Webcast
November 04, 2013 16:30 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 4, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, will report third...
OXiGENE Presents Preclinical Data Demonstrating Significant Antitumor Activity of ZYBRESTAT(R) in Pancreatic Neuroendocrine Tumor Model
October 21, 2013 09:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced the...
OXiGENE to Present Preclinical Data Demonstrating Antitumor Activity of ZYBRESTAT(R) in Pancreatic Neuroendocrine Tumor Model
October 15, 2013 16:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 15, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that...